A NEW STANDARD OF CARE FOR RIGHT HEART FAILURE

CE & FDA Approved for Acute Right Ventricular Failure



Impella RP®

Heart Pump

ABIOMED®

Recovering hearts. Saving lives.

Impella RP®

UNLOAD THE RIGHT VENTRICLE WITH CONTINUOUS HEMODYNAMIC SUPPORT.

The Impella RP System is the first and only percutaneous heart pump FDA approved for right heart support and also CE approved. The Impella RP is part of Abiomed's comprehensive heart recovery product portfolio that provides immediate hemodynamic benefit for patients with ventricular dysfunction.

The Impella RP System pumps blood from the inferior vena cava to the pulmonary artery.

The Impella RP may enable right ventricular recovery in patients.

Patient Identification with Right Ventricle Failure

- Post cardiac surgery / transplant
- Post-AMI cardiogenic shock
- Post-LVAD

The Only Percutaneous Heart Pump Approved for Right Heart Support

- Provides right ventricular unloading with 4.0+ L/min of continuous flow for immediate improvement in hemodynamic performance*
- Indicated for use for up to 14 days in patients with a body surface area of ≥1.5 m^2
- Enables biventricular support**

*As demonstrated in the RECOVER RIGHT clinical trial
**When used in conjunction with a durable LVAD system or if Impella has already been placed for left heart support.

Sustained Hemodynamic Improvement After Impella RP Removal[1]



RECOVERING HEARTS. SAVING LIVES.®



Catheter Diameter: **11Fr**
Cannula Diameter: **22Fr**
Flow Rate: **4.0+L/min**

Easy To Deliver

- Percutaneous, single venous access performed with routine transcatheter techniques
- Anatomically optimized, low profile catheter for easy placement & positioning in right heart anatomy
- Quick set-up and lack of circuit prep enables rapid initiation of hemodynamic support
- Hemostatic valve on 23 Fr x 30 cm peel-away sheath

Built On The Proven Impella Platform

- More than 100,000 patients treated with the Impella device
- Low complication rate^
- Low anticoagulation profile^^
- Utilizes same console as left sided Impella devices

^RECOVER RIGHT / Impella RP Prospective PAS
^^As compared to LVAD and ECMO procedures

Impella® Heart Pumps

ADVANCING THE FIELD OF HEART RECOVERY.

See how the Impella device provides hemodynamic support for your highest-risk patients.

To learn more visit **www.abiomed.com/RP**



37% Incidence of Right Ventricular Failure in Cardiogenic Shock[2]

Many patients experience right heart failure when in cardiogenic shock. Impella RP can support patients and may enable recovery.

References: **1.** *Anderson et al. The RECOVER RIGHT Study* **2.** *Lala, Anuradha et al., Right Ventricular Dysfunction in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Hemodynamic Analysis of the Should we emergently revascularize Occluded Coronaries for Cardiogenic shock (SHOCK) Trial and Registry, Journal of Cardiac Failure , Volume 22 , Issue 8 , S39*

INDICATION FOR USE IN THE EUROPEAN UNION

The Impella RP System (percutaneous pump for right ventricular support) is intended for clinical use in cardiology, in cardiac surgery, and intensive care unit for up to 14 days for the following indications, as well as others:

- Acute or transient reduction of the right ventricular function (eg, postcardiotomy low output syndrome)
- Cardiogenic shock as a consequence of a posterior myocardial infarction with right ventricular heart failure
- Right heart support during coronary beating heart bypass surgery, especially for patients with a reduced preoperative cardiac output or for patients having a high risk of developing a postoperative low output syndrome for other reasons
- Right ventricular heart failure after implantation of a left ventricular assist device
- Therapy unresponsive arrhythmias with a reduction of right ventricular output
- Heart failure and/or cardiogenic shock as a consequence of refractory ventricular arrhythmias, as well as a consequence of sustained supraventricular arrhythmias, causing haemodynamic compromise.

Important Risk Information for Impella RP®

CONTRAINDICATIONS IN THE EUROPEAN UNION

- Arteriosclerosis, in particular calcification or other disorders of the pulmonary artery wall
- Mechanical valves, severe valvular stenosis or valvular regurgitation of the tricuspid valve or pulmonary valve
- Mural thrombus of the right atrium or vena cava
- Anatomic conditions precluding insertion of the pump
- Other illnesses or therapy requirements precluding use of the pump
- Presence of a vena caval filter or caval interruption device, unless there is clear access from the femoral vein to the right atrium that is large enough to accommodate a 22 Fr catheter

POTENTIAL ADVERSE EVENTS

Hemolysis, bleeding, immune reaction, embolism, thrombosis, vascular injury through to angionecrotomy, infection and septicemia, endocardiac injuries due to attachment of the pump to the inferior vena cava, pump failure, loss of pump components following a defect, patient dependency on the pump after use of support.

In addition to the risks above, there are other **WARNINGS** and **PRECAUTIONS** associated with Impella RP.
Visit ***www.abiomed.com/impella/impella-rp*** to learn more.

To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit:
www.protectedpci.eu/en/therapy/product-variations/

CE 0482

IMP-404-17 EU-EN (v2.0)
Educational material intended for European customers under CE Mark

ABIOMED

EC REP **Abiomed Europe GmbH**
Neuenhofer Weg 3
52074 Aachen, Germany
Voice: +49 (241) 8860-0
Facsimile: +49 (241) 8860-111
Email: europe@abiomed.com

ABIOMED, Inc.
22 Cherry Hill Drive, Danvers, MA 01923 USA
Voice: +1 978-646-1400
Facsimile: +1 978-777-8411
Email: marketing@abiomed.com

Clinical Support
24 hours per day, 7 days a week:
+49(0) 1805 2246633 (EU)
+1-800-422-8666 (US)

www.abiomed.com